rpx7009 has been researched along with Pneumonia* in 2 studies
1 review(s) available for rpx7009 and Pneumonia
| Article | Year |
|---|---|
New evidence in severe pneumonia: meropenem-vaborbactam.
The appearance and spread of new mechanisms of bacterial resistance to antibiotics is a serious health problem. One of the most difficult resistance mechanisms to treat is the production of carbapenemases. Carbapenemase KPC is one of those mechanisms with few therapeutic options. Meropenem-vaborbactam has shown great efficacy against this type of microorganism, both from a clinical and microbiological point of view. Its good pharmacokinetics, including in the lung, and its safety profile make meropenem-vaborbactam an excellent therapeutic option. Finally, the absence of resistance genesis during treatment seems to indicate that its efficacy will be long-lasting. Topics: Anti-Bacterial Agents; Boronic Acids; Humans; Meropenem; Pneumonia | 2022 |
1 other study(ies) available for rpx7009 and Pneumonia
| Article | Year |
|---|---|
Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018.
Meropenem-vaborbactam is approved to treat hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), in Europe. Meropenem-vaborbactam activity was evaluated against 3,193 Topics: Anti-Bacterial Agents; Boronic Acids; Enterobacteriaceae; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia; Whole Genome Sequencing | 2020 |